Relapse rate of non-HR patients with or without TP53/KRAS variants
| . | Relapse . | No relapse . | Total . |
|---|---|---|---|
| TP53/KRAS positive | 6 (35%) | 11 | 17 |
| TP53/KRAS negative | 36 (20%) | 144 | 180 |
| Total | 42 (21%) | 155 | 197 |
| . | Relapse . | No relapse . | Total . |
|---|---|---|---|
| TP53/KRAS positive | 6 (35%) | 11 | 17 |
| TP53/KRAS negative | 36 (20%) | 144 | 180 |
| Total | 42 (21%) | 155 | 197 |
In the group of patients with non-HR treatment response, 35% of patients with TP53 and/or KRAS variants and 20% of the patients without such variants experienced a relapse.